Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
Prediction of pneumonia following neoadjuvant chemoradiotherapy in patients with oesophageal cancer.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Frederiks M L, Berbée M, Schuit E, van Laarhoven H W M, van Rossum P S N, van Kesteren Z, van Berge Henegouwen M I, Meijer G J, Mook S, Ruurda J P, Nuyttens J J, Mostert B, Rütten H, Klarenbeek B, Hartogh M D den, Sosef M, Canters R, Verhoeven R H A, van Etten B, Langendijk J A, Wijnhoven B P L, Muijs C T, MODELS consortium
Аннотация
BACKGROUND AND PURPOSE: Pneumonia is a frequent, severe complication following neoadjuvant chemoradiotherapy (nCRT) and esophagectomy for oesophageal cancer, adversely affecting outcomes. We aimed to develop a model to accurately predict this risk.
MATERIAL AND METHODS: This multicentre, retrospective study included oesophageal cancer patients (cT1-4N0-3M0) undergoing nCRT +/- esophagectomy (CROSS regimen) treated between 2015-2021. The endpoint was grade ≥2 pneumonia (CTCAE v5.0) within six months post-nCRT. To handle high dimensionality, principal component analysis (PCA) was used to condense lung and heart DVH patterns into interpretable dose patterns. A logistic regression model was developed and validated using internal-external cross-validation to assess discrimination, calibration, and heterogeneity across centres.
RESULTS: A total of 1,459 patients across five centers were included for the final model development; 314 (22%) of which developed pneumonia. The developed model included pre-existing lung disease, diabetes, esophagectomy, and three PCA-derived dose patterns (overall heart/lung dose, heart-versus-lung dose, and low-dose areas). The model showed low heterogeneity (I2 = 0% for all measures), fair discrimination (pooled AUC 0.68; 95% CI, 0.63-0.72), and excellent calibration (slope 0.91; 95% CI, 0.56-1.26; calibration-in-the-large 0.02; 95% CI, -0.14-0.18).
CONCLUSION: We developed and validated a generalizable NTCP model for pneumonia prediction in oesophageal cancer patients. This multicentre pulmonary NTCP model showed good calibration and homogeneous performance between centres. It offers a promising tool to personalize treatment by facilitating radiotherapy plan optimization and treatment/technique selection.
MATERIAL AND METHODS: This multicentre, retrospective study included oesophageal cancer patients (cT1-4N0-3M0) undergoing nCRT +/- esophagectomy (CROSS regimen) treated between 2015-2021. The endpoint was grade ≥2 pneumonia (CTCAE v5.0) within six months post-nCRT. To handle high dimensionality, principal component analysis (PCA) was used to condense lung and heart DVH patterns into interpretable dose patterns. A logistic regression model was developed and validated using internal-external cross-validation to assess discrimination, calibration, and heterogeneity across centres.
RESULTS: A total of 1,459 patients across five centers were included for the final model development; 314 (22%) of which developed pneumonia. The developed model included pre-existing lung disease, diabetes, esophagectomy, and three PCA-derived dose patterns (overall heart/lung dose, heart-versus-lung dose, and low-dose areas). The model showed low heterogeneity (I2 = 0% for all measures), fair discrimination (pooled AUC 0.68; 95% CI, 0.63-0.72), and excellent calibration (slope 0.91; 95% CI, 0.56-1.26; calibration-in-the-large 0.02; 95% CI, -0.14-0.18).
CONCLUSION: We developed and validated a generalizable NTCP model for pneumonia prediction in oesophageal cancer patients. This multicentre pulmonary NTCP model showed good calibration and homogeneous performance between centres. It offers a promising tool to personalize treatment by facilitating radiotherapy plan optimization and treatment/technique selection.